Exploring the potential of as a diagnostic biomarker in prostate cancer.

Background: Exploring the potential of as a diagnostic biomarker in prostate cancer.

Methods: Expression of the lncRNA was analyzed between normal and tumor samples in the GDC TCGA PRAD (Genomic Data Commons: The Cancer Genome Atlas Prostate Adenocarcinoma Collection) dataset. Disease progression-related clinicopathological parameters such as serum PSA level (ng/ml) and Gleason score were associated with the expression of using the same GDC TCGA PRAD dataset. To validate these findings, the expression of was checked in our sample set of 15 PCa (prostate cancer) and 15 BPH (benign hypertrophy of the prostate) patients.

Results: In the GDC TCGA PRAD dataset, the expression of the lncRNA was significantly downregulated in prostate cancer tissue samples ( = 492) compared to adjacent normal ( = 52;  < 0.0001), and, there was a significant negative correlation between the expression of the lncRNA and the serum PSA level ( < 0.01). However, no significant association was found between the lncRNA expression and the Gleason score ( > 0.05). In this study, it was found that was downregulated in PCa tissue samples compared to BPH samples ( > 0.05). In the GDC TCGA PRAD dataset, it was revealed that BOLA3-DT could serve as an excellent diagnostic marker with a sensitivity of 86.9% and a specificity of 84.6% (AUC-0.916).

Conclusion: LncRNA , a novel long non-coding RNA, was found to be downregulated in prostate cancer. The expression of the lncRNA can serve as a diagnostic marker in prostate cancer.